{"prompt": "['Charit\u00e9 Universit\u00e4tsmedizin Berlin', 'Prof. Dr. med. Dominik Modest', 'FIRE-9 PORT', '28-Sep-2021', 'EudraCT no. 2020-006144-18', 'Protocol Version 3.0', 'secondary endpoints are overall survival, safety, quality of life, number and type of treatments', '(including efficacy) beyond study participation, PFS and OS according to circulating tumor', 'DNA at baseline (ctDNA positive VS. negative), outcome in molecular subgroups, local control', 'of lesions according to ablative technique (surgery VS. ablation vs. radiation). These endpoints', 'and subgroup analyses are foreseen to identify those patient populations who benefit', 'most/least from a post-resection/ablation therapy to allow for a potential fine-tuning of', 'treatment in the future.', 'As part of the translational research project, blood samples are collected as part of the', 'structured follow-up to create a collection of patient material with and without relapse.', 'Moreover, the relapses will be recorded as part of the study protocol, including the collection', 'of additional tumor tissue and blood samples, if possible, at the time of relapse. Understanding', 'the genetic and molecular tumor characteristics, their longitudinal changes and correlating this', 'with the baseline characteristics (prior systemic therapy, ablative technique used, resection', 'status) and clinical outcome will provided the most complete set of data to answer whether', 'patients - and if so, which patients - benefit from an additive/adjuvant therapy after local', 'treatment of metastases.', 'In summary, the optimal oncological management after removal of metastases is still unclear', 'and results of this trial may therefore be practice-changing.', '4.4 Ethical Considerations and Benefit-Risk Assessment', 'Patients with treated metastases from colorectal cancer represent a high-risk cohort for', 'development of new metastases and consecutively death. Therefore, intervention with', 'systemic therapy appears clearly justified, also taking into account that intervention with a', 'combination regimen (fluoropyrimidine plus oxaliplatin) is accepted in patients with lower stage', '(UICC III) of disease and less risk of relapse. The intervention - although not recommended', 'by the actual German guidelines and supported by data - is often discussed in tumor boards,', 'regularly leading to \"individual\" solutions without data that justify chemotherapy in these', 'patients - which is also in accordance with European perspectives (ESMO). Participating', 'patients will therefore receive either standard of care on the basis of available evidence (watch', 'and wait-observation including structured follow-up), or as intervention, up to 6 months of', 'therapy that was so far not evaluated in this clinical setting that invokes subclinical metastases', 'in the majority of patients at the time of study start. Therefore, a potential disadvantage,', 'although possible, seems unlikely. The study will therefore either provide a basis for routine', 'treatment of patients or alternatively confirm that additive treatment does not provide a relevant', 'benefit and should not be promoted. These observations will be made in the context of a quality', 'of life assessment. The trial will be conducted according to the declaration of Helsinki, German', 'laws and with respect to protection of data privacy.', 'Confidential', 'Page 31 of 79']['Charit\u00e9 Universit\u00e4tsmedizin Berlin', 'Prof. Dr. med. Dominik Modest', 'FIRE-9 PORT', '28-Sep-2021', 'EudraCT no. 2020-006144-18', 'Protocol Version 3.0', '5', 'Methodology', '5.1 Trial Population', 'Investigators will recruit patients directly during regular clinical consultation visits in the', 'respective center, e.g. after being discussed in a multidisciplinary tumor board. All study', 'related investigations and enrolment of patients will only be performed after a written consent', 'was collected using the ethics committee approved patient information and consent forms', '(refer to protocol section 10.4).', 'Patients fulfilling the inclusion-/exclusion criteria (see below) will be captured online in the', 'eCRF as screening patients to obtain a patient number which is used for pseudonymized', 'identification throughout the study.', '5.1.1 Inclusion Criteria', 'Participants are eligible to be included in the trial only if all of the following criteria apply:', \"1. Patient's signed informed consent.\", '2.', \"Patient's age >18 years at the time of signing the informed consent.\", '3.', 'Histologically confirmed adenocarcinoma of the colon or rectum.', '4.', 'Resected (R0 or R1) and/or effectively treated metastases (all techniques allowed) of', 'colorectal cancer within 3-10 weeks before randomization AND resected primary tumor', '(synchronous or metachronous).', '5. Absence of significant active wound healing complications (if applicable) prior to', 'randomization. Resolved wound healing complications after resection/ablation are', 'acceptable for inclusion into the trial.', '6. No radiographic evidence of active metastatic disease at study entry in a CT and/or MRI', 'scan not older than 8 weeks. Pre-surgery/ablation images are eligible for the study if all', 'lesions have been addressed in the interval.', '7. ECOG performance status 0-2.', '8. Adequate bone marrow, hepatic and renal organ function, defined by the following', 'laboratory test results:', 'Absolute neutrophil count 1.5 X 10%/L (1500/L)', 'Hemoglobin 80 g/L (8 g/dL)', 'Platelet count 100 x10%/L (100000/L) without transfusion', 'Total serum bilirubin of 1.5 X upper limit of normal (ULN)', 'Aspartate aminotransferase (AST/GOT) < 3.0 x ULN.', 'Calculated glomerular filtration rate (GFR) according to Cockcroft-Gault formula or', 'according to MDRD 50 mL/min or serum creatinine < 1.5 X ULN', '9.', 'Patients without anticoagulation need to present with an INR < 1.5 X ULN and PTT < 1.5', 'X ULN. Patient with prophylactic or therapeutic anticoagulation are allowed into the trial.', 'Confidential', 'Page 32 of 79']\n\n###\n\n", "completion": "END"}